Pharmacokinetic properties of Gammagard Liquid 10% (KIOVIG) administered intravenously and subcutaneously to patients with primary immunodeficiency diseases (PID)

被引：0
|
作者：
Schiff, R., I [1 ]
Leibl, H. [1 ]
Engl, W. [1 ]
机构：
[1] Baxter Healthcare Corp, Westlake Village, CA USA
来源：
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2008年 / 154卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases
    Hans D. Ochs
    Sudhir Gupta
    Peter Kiessling
    Uwe Nicolay
    Melvin Berger
    Journal of Clinical Immunology, 2006, 26 : 265 - 273
  • [22] Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases
    Ochs, Hans D.
    Gupta, Sudhir
    Kiessling, Peter
    Nicolay, Uwe
    Berger, Melvin
    JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (03) : 265 - 273
  • [23] Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients
    Rubinstein, A.
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    McCoy, B.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    Grossman, W. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB213 - AB213
  • [24] Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases
    Navarro-Mora, Graciela
    Alberti, Joan J.
    Mondou, Elsa
    Vilardell, David
    Vicente Torres, Juan
    Ayguasanosa, Jaume
    Paez, Antonio
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 104
  • [25] THE HALF-LIVES OF IGG SUBCLASSES AND SPECIFIC ANTIBODIES IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY WHO ARE RECEIVING INTRAVENOUSLY ADMINISTERED IMMUNOGLOBULIN
    MANKARIOUS, S
    LEE, M
    FISCHER, S
    PYUN, KH
    OCHS, HD
    OXELIUS, VA
    WEDGWOOD, RJ
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1988, 112 (05): : 634 - 640
  • [26] Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases
    Schiff, RI
    Williams, LW
    Nelson, RP
    Buckley, RH
    Burks, W
    Good, RA
    JOURNAL OF CLINICAL IMMUNOLOGY, 1997, 17 (01) : 21 - 28
  • [27] POPULATION PHARMACOKINETIC ANALYSIS OF IGPRO10 IN JAPANESE PATIENTS WITH PRIMARY IMMUNODEFICIENCY.
    Luo, D.
    Tortorici, M.
    Hofmann, J.
    Rojavin, M.
    Baheti, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S94
  • [28] Multicenter Crossover Comparison of the Safety and Efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in Patients with Primary Immunodeficiency Diseases
    Richard I. Schiff
    Larry W. Williams
    Robert P. Nelson
    Rebecca H. Buckley
    Wesley Burks
    Robert A. Good
    Journal of Clinical Immunology, 1997, 17 : 21 - 28
  • [29] ASSESSING THE VIAL REDUCTION ASSOCIATED WITH 30 GRAM GAMMAGARD LIQUID VIAL USE IN TREATING PRIMARY IMMUNODEFICIENCY (PI) PATIENTS IN REAL WORLD
    Iyer, Ravi
    Xiong, Yan
    Luo, Michelle
    JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (03) : 707 - 707
  • [30] EVALUATION OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS (PK) OF GAMMAPLEX® 10% VERSUS GAMMAPLEX® 5 % IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PID)
    Wasserman, Richard L.
    Stein, Mark R.
    Jolles, Stephen
    Norton, Miranda
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 227 - 228
12345